Kalquest

Kalquest

Manufacturer:

Novell Pharma

Distributor:

Averroes Pharma
Concise Prescribing Info
Contents
Ca polystyrene sulfonate
Indications/Uses
Hyperkalaemia resulting from acute or chronic renal failure.
Dosage/Direction for Use
15-30 g daily in 2-3 divided doses.
Contraindications
Hypersensitivity to Ca polystyrene sulfonate or polystyrene sulfonate resins. Conditions associated w/ hypercalcaemia eg, hyperparathyroidism, multiple myeloma, sarcoidosis, metastatic carcinoma; obstructive bowel disease; plasma K levels >5 mmol/L. PO in neonates.
Special Precautions
Hypokalaemia; other electrolyte disturbance; clinically significant constipation. Monitor all applicable electrolyte disturbance. Avoid aspiration. Not to be used w/ Mg-containing laxatives. Concomitant use w/ sorbitol. Pregnancy & lactation. Risk of digestive haemorrhage or colonic necrosis in premature or low birth wt infants. Not to be given PO in neonates.
Adverse Reactions
Hypokalaemia, hypercalcaemia, hypomagnesaemia; gastric irritation, anorexia, nausea, vomiting, constipation, diarrhoea.
Drug Interactions
Cases of intestinal necrosis & other serious GI ARs w/ sorbitol. Reduced K-binding effectiveness w/ cation-donating agents. Systemic alkalosis w/ non-absorbable cation-donating antacids & laxatives eg, Mg hydroxide, Al carbonate. Intestinal absorption w/ Al hydroxide. Exaggerated digitalis toxic effects. Decreased lithium, l-thyroxine absorption.
ATC Classification
V03AE01 - polystyrene sulfonate ; Belongs to the class of drugs used in the treatment of hyperkalemia and hyperphosphatemia.
A07XA03 - calcium compounds ; Belongs to the class of other antidiarrheals.
Presentation/Packing
Form
Kalquest powd for oral susp 5 g
Packing/Price
(mocha flavour) 5 g x 30 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in